KRT19 and Patent ductus arteriosus: In contrast, s/c tumors formed with the Krt19-edited PDA cells did not stain with antibodies to either KRT19 or CXCL12, and intratumoral CD3+ T cells were frequent (Fig. 4A and SI Appendix, Fig. S6C).